CPM Antibody

What is CPM and what is its function in cellular biology?

Carboxypeptidase M (CPM) is a membrane-bound enzyme that specifically removes C-terminal basic residues (Arg or Lys) from peptides and proteins. It is believed to play important roles in the control of peptide hormone and growth factor activity at the cell surface, and in the membrane-localized degradation of extracellular proteins . This enzyme is anchored to the plasma membrane and participates in regulatory processes that influence cell growth, differentiation, and function through its effect on bioactive peptides.

What are the standard applications for CPM antibodies in research?

CPM antibodies are utilized across multiple research applications, with validated protocols for several key techniques:

These applications enable researchers to detect and quantify CPM expression in various experimental systems .

Which cell types or tissues express high levels of CPM?

CPM expression has been documented in various human tissues and cell types:

This tissue distribution pattern makes CPM antibodies particularly useful for studying renal, placental, and progenitor cell biology .

How can CPM antibodies be utilized in stem cell and progenitor cell research?

Recent studies have established CPM as a valuable marker for identifying and isolating specific progenitor cell populations. CPM antibodies have proven particularly useful in stem cell research through the following applications:

• Identification of respiratory progenitors: CPM serves as a marker for airway and alveolar progenitor cells derived from human induced pluripotent stem (iPS) cells .

• Cell sorting and enrichment: Using flow cytometry with CPM antibodies, researchers can isolate CPM-expressing cell populations that demonstrate enhanced potential to differentiate into specialized respiratory epithelial cells .

• Developmental tracking: CPM expression can be monitored during differentiation processes to assess commitment to specific lineages, particularly in lung development models .

• Hepatic progenitor identification: Beyond respiratory applications, CPM also marks hepatic progenitor populations, expanding its utility in liver development and regeneration research .

Cell populations that highly express CPM also frequently express NKX2-1, a critical transcription factor and marker for respiratory cells, making dual analysis particularly informative in developmental biology studies .

What is the significance of CPM as a marker in respiratory cell development?

CPM has emerged as a significant marker in respiratory cell development research, with multiple studies highlighting its importance:

CPM expression identifies progenitor populations committed to respiratory fates during the differentiation of human iPS cells into lung cell lineages. This surface marker enables researchers to isolate and study cells at critical developmental stages . Recent studies have demonstrated that cell populations with high CPM expression also highly express NKX2-1, a master transcription factor for respiratory development .

The practical significance of this relationship was demonstrated in experiments where human iPS cells were differentiated into lung progenitor cells, then dissociated and sorted based on CPM expression using flow cytometry. The CPM-high populations were subsequently found to be particularly suitable for differentiation into both alveolar and airway epithelial cells .

This application of CPM antibodies has been cited in several significant publications, including work in Nature Methods and Journal of Clinical Investigation, highlighting the growing importance of CPM as a developmental marker .

How do different CPM antibody formats affect experimental outcomes?

Different CPM antibody formats significantly influence experimental outcomes across various applications:

For flow cytometry applications particularly focused on progenitor cell isolation, directly conjugated antibodies like the Red Fluorochrome(635)-conjugated anti-CPM antibody offer advantages in multiparameter analyses, while unconjugated formats allow for greater signal amplification in Western blot applications .

What are the considerations for multiplex experiments involving CPM antibodies?

Multiplex experiments involving CPM antibodies require careful consideration of several factors to ensure reliable results:

• Antibody Compatibility:

  • When combining multiple antibodies, select those raised in different host species or of different isotypes to avoid cross-reactivity

  • For flow cytometry panels including CPM, consider using the directly conjugated Red Fluorochrome(635)-CPM antibody to minimize fluorescence spillover

• Spectral Considerations:

  • CPM antibody conjugates should be selected with emission spectra that minimize overlap with other fluorophores in the panel

  • Proper compensation controls are essential when CPM antibodies are used alongside other fluorescent markers

• Protocol Optimization:

  • For co-staining experiments in IHC or IF, sequential rather than simultaneous staining may be necessary

  • Titrate each antibody individually before combining them in multiplex experiments

  • Flow cytometry applications typically require dilutions of 1:10 for conjugated and 1:100-200 for unconjugated CPM antibodies

• Controls:

  • Include appropriate isotype controls for each antibody in the panel

  • Single-stained samples are essential for setting up proper compensation in flow cytometry

  • Include unstained controls to establish autofluorescence baselines

When applied correctly, these considerations can enable successful multiplex experiments, such as co-staining for CPM and NKX2-1 in lung progenitor cell research .

What are the optimal conditions for using CPM antibodies in Western blot applications?

For optimal Western blot results with CPM antibodies, researchers should follow these validated conditions:

These conditions have been validated in multiple human cell lines (SiHa, HeLa, U20S) and tissue lysates (placenta, fetal liver, fetal kidney), demonstrating consistent and specific detection of CPM protein .

How should CPM antibodies be handled and stored to maintain activity?

Proper handling and storage are crucial for maintaining CPM antibody activity and performance:

For lyophilized antibodies:

• Store at -20°C for up to one year from date of receipt

• Reconstitute according to manufacturer's instructions

• After reconstitution, aliquot to avoid repeated freeze-thaw cycles

For liquid formulations:

• Store at 4°C for short-term use (up to one month)

• For long-term storage, keep at -20°C for up to six months

• Some formulations contain glycerol (40-50%) and 0.05% sodium azide as preservatives

Working solution preparation:

• Prepare fresh dilutions immediately before use

• Use high-quality, sterile buffers for dilution

• Return stock solutions to recommended storage conditions promptly

Avoid repeated freeze-thaw cycles as they significantly reduce antibody activity. Following these guidelines will help ensure consistent performance in applications ranging from Western blot to flow cytometry .

What are the recommended titrations for CPM antibodies in flow cytometry?

Optimal titration of CPM antibodies for flow cytometry applications varies by antibody format and experimental conditions:

When establishing optimal concentrations, researchers should:

• Perform a titration series (e.g., 1:10, 1:50, 1:100, 1:200)

• Evaluate signal-to-noise ratio rather than just maximum signal intensity

• Include appropriate isotype controls at matching concentrations

• Consider cell-specific factors (CPM expression levels may vary significantly between cell types)

For progenitor cell isolation applications, such as sorting lung progenitor cells differentiated from human iPS cells, the manufacturer's recommended starting dilution has been validated in published studies .

How do fixation and antigen retrieval methods affect CPM antibody performance in IHC?

Fixation and antigen retrieval significantly impact CPM antibody performance in immunohistochemistry applications:

Fixation considerations:

• Formalin/PFA-fixed paraffin-embedded sections are standard for CPM detection

• Overfixation can mask CPM epitopes, potentially reducing signal intensity

• Fresh frozen sections may preserve antigenicity but can compromise tissue morphology

Antigen retrieval methods:

• Heat-mediated antigen retrieval is essential for optimal CPM detection in FFPE tissues

• Tris/EDTA buffer at pH 9.0 has been successfully validated with anti-CPM antibodies

• Complete antigen retrieval before proceeding with the IHC staining protocol

Antibody dilutions for IHC:

• Unpurified antibodies: typically 1:50 dilution

• Purified antibodies: 1:100-1:500 dilution range

• Higher dilutions may reduce background while maintaining specific signal

Detection systems:

• HRP-conjugated secondary antibodies at 1:500 dilution work well with rabbit anti-CPM primary antibodies

• Counterstaining with hematoxylin provides effective nuclear contrast

CPM antibodies have been successfully used on various human tissues including endometrium, hepatocellular carcinoma, uterus, and kidney, though optimization may be required for each specific tissue type .

How should researchers interpret variations in CPM expression levels?

Interpreting variations in CPM expression requires consideration of both biological context and technical factors:

Biological context assessment:

• CPM expression naturally varies between tissue types (kidney, placenta, liver show different baseline levels)

• During development, CPM marks specific progenitor populations (e.g., airway, alveolar, and hepatic progenitor cells)

• Expression may change during differentiation processes

Quantification approaches:

• Western blot: Normalize CPM band intensity to loading controls (GAPDH, β-actin)

• Flow cytometry: Assess both percentage of positive cells and mean fluorescence intensity

• IHC: Consider both staining intensity and percentage of positive cells in the region of interest

Reference points for comparison:

• Include appropriate positive controls (e.g., kidney tissue for Western blot)

• Compare expression between experimental conditions consistently

• Consider temporal changes in expression when relevant

When analyzing CPM expression in differentiating stem cells, researchers should note that high CPM expression correlates with NKX2-1 expression in cells committed to respiratory lineages. This pattern provides functional context for interpreting CPM expression significance in developmental systems .

What controls are essential for validating CPM antibody specificity?

Rigorous validation of CPM antibody specificity requires multiple control strategies:

For flow cytometry applications particularly, isotype controls matching the CPM antibody's host species and immunoglobulin class are essential for setting appropriate gates and distinguishing specific from non-specific binding .

When researchers queried about cross-reactivity of anti-CPM antibody (A01650) with feline tissues, while human reactivity was confirmed, cross-species validation was recommended before experimental use—highlighting the importance of appropriate controls when extending antibody use to new species .

How can researchers troubleshoot non-specific binding with CPM antibodies?

To resolve non-specific binding issues with CPM antibodies, researchers can implement these troubleshooting strategies:

Blocking optimization:

• Increase blocking time (from 1 hour to 2 hours or overnight)

• Test alternative blocking agents (5% non-fat dry milk, 5% BSA, commercial blockers)

• Add 0.1-0.3% Triton X-100 or Tween-20 to reduce hydrophobic interactions

Antibody dilution adjustment:

• Perform titration series to determine optimal concentration

• For Western blot, try higher dilutions (1:2500-1:5000) to reduce background

• For IHC, dilutions of 1:100-1:500 for purified antibodies may improve signal-to-noise ratio

Protocol refinement:

• Increase wash number and duration between steps

• Use buffers with appropriate salt concentration (TBS with 0.1% Tween-20)

• For flow cytometry, include Fc receptor blocking reagents

Application-specific approaches:

• For IHC: Include peroxidase quenching step before antibody incubation

• For immunofluorescence: Use autofluorescence quenching reagents

• For flow cytometry: Optimize compensation to account for spectral overlap

If persistent non-specific binding occurs despite these measures, consider testing alternative CPM antibody clones, as some formats may perform better with specific sample types or applications .

What quantitative methods are appropriate for analyzing CPM expression data?

Quantitative analysis of CPM expression requires appropriate methods based on the experimental technique:

For Western blot quantification:

• Perform densitometric analysis of band intensity using ImageJ or similar software

• Normalize to housekeeping proteins (β-actin, GAPDH) to account for loading differences

• Use relative quantification comparing experimental samples to control conditions

For flow cytometry analysis:

• Report percentage of CPM-positive cells using consistent gating strategies

• Measure mean/median fluorescence intensity to assess expression levels

• Apply appropriate statistical tests (t-test, ANOVA) for population comparison

• For sorting experiments, analyze post-sort purity and functional characteristics of isolated populations

For immunohistochemistry quantification:

• Apply H-score method: intensity score (0-3) × percentage of positive cells

• Consider automated image analysis for unbiased assessment

• Compare expression patterns across multiple samples and conditions

Statistical considerations:

• Include sufficient biological replicates (minimum n=3, preferably more)

• Apply appropriate statistical tests based on data distribution

• Report both statistical significance and effect size for proper interpretation

For lung progenitor cell research using CPM as a marker, quantifying both percentage of positive cells and their mean fluorescence intensity provides complementary data that can be correlated with functional outcomes such as differentiation potential .

How is CPM antibody being used in developmental biology research?

CPM antibody has become an invaluable tool in developmental biology, particularly in studying cell lineage specification during organ development:

Researchers have leveraged CPM antibodies to identify and isolate lung progenitor cells during differentiation from pluripotent stem cells. By using flow cytometry with CPM antibodies, they've demonstrated that CPM-high cell populations are ideally suited for differentiation into both alveolar and airway epithelial cells .

This application has been cited in high-impact publications, including studies in Nature Methods and Journal of Clinical Investigation, establishing CPM as an important developmental marker for respiratory lineages . The co-expression of CPM with NKX2-1, a master regulator of lung development, provides researchers with a surface marker that enables isolation of viable cells committed to respiratory fates .

Beyond respiratory development, CPM antibodies have also been utilized to study hepatic progenitor populations, suggesting a broader application in understanding organ development and regeneration across multiple tissue types .

What are the considerations when using CPM antibodies alongside therapeutic antibody research?

When incorporating CPM antibodies into research involving therapeutic antibodies, several important considerations emerge:

• Compatibility with analytical methods:

  • Size-exclusion chromatography (SEC) is commonly used to analyze therapeutic monoclonal antibodies, separating high and low molecular weight species from the monomer based on hydrodynamic radius

  • When integrating CPM antibody detection in such systems, consider potential interactions or interference with SEC separation methods

• Sample preparation harmonization:

  • Therapeutic antibody research often requires stringent sample preparation protocols

  • CPM antibody detection methods should be harmonized with these requirements to allow parallel analysis

• Quality control considerations:

  • In therapeutic antibody manufacturing, controlling size variants is considered a critical quality attribute

  • When CPM is used as a marker in cell systems producing therapeutic antibodies, proper controls must be implemented

• Platform method compatibility:

  • Platform analytical methods streamline therapeutic antibody analysis

  • CPM detection protocols should be compatible with such platform approaches when used in combination

This integration is particularly relevant when studying CPM expression in cell systems being evaluated for therapeutic antibody production or when CPM antibodies are used alongside therapeutic antibodies in complex experimental designs .

The pharmaceutical industry's emphasis on reproducibility, robustness, and validation aligns with the rigorous approach needed for reliable CPM antibody applications in research contexts .